Clinical Trial Update: Efficacy and Safety of Panobinostat (LBH589) in Patients With Refractory de Novo or Secondary Acute Myelogenous Leukemia (AML) [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating panobinostat in patients with refractory de novo or secondary acute myeloid leukemia. The study reports on efficacy and safety outcom…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Panobinostat (Panobinostat)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Refractory Leukemia, Acute Myelogenous Leukemia | Phase 2 | Status: COMPLETED | Results posted: 2016-09-09